TrialAnnals of the rheumatic diseases2018

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Dinesh Khanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.